

Notice of Change in Distribution Model for Cometriq®

This notice provides information for 340B covered entities regarding the distribution of Cometriq® (cabozantinib). Cometriq® is an orphan drug that is approved to treat a very small patient population. To facilitate patient care, Exelixis has historically distributed Cometriq® through a specialty pharmacy. To enable access by 340B covered entities who wish to dispense Cometriq® to patients themselves, however, Exelixis has negotiated an agreement with a national distributor, McKesson Plasma and Biologics, to distribute Cometriq® to these entities. Please contact McKesson Plasma and Biologics directly at 877-625-2566 to place orders for Cometriq®. Your patients may also continue to access Cometriq® through a specialty pharmacy by contacting the Exelixis® Access Services (EASE) program at 1-855-253-EASE (1-855-253-3273).

Exelixis takes its obligations under the 340B program seriously and makes every effort to ensure that Cometriq® is available to 340B covered entities in a manner that is no more restrictive than it is for non-340B entities. If you have any questions regarding access to Cometriq®, please contact Brenda Alexander at 650-837-7345.